PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has announced its financial results and business updates for the third quarter of 2024, highlighting significant progress in its clinical trials and strategic initiatives. The company is broadening the Phase 1 CALiPSO-1 trial for its innovative CNTY-101 therapy to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy.
In the ongoing Phase 1 ELiPSE-1 study, CNTY-101 demonstrated an overall response rate of 83% at Dose Level 3B among patients with relapsed or refractory B-cell lymphomas, maintaining a favorable safety profile. Brent Pfeiffenberger, CEO of Century Therapeutics, commented, “Broadening our strategic focus in autoimmune indications will give us greater insight into the potential of CNTY-101 in an underserved therapeutic category that we believe is uniquely suited to allogeneic iNK cell therapies.”
Financially, Century ended the third quarter with $244.7 million in cash, cash equivalents, and investments, projecting this will sustain operations into the second half of 2026. The company reported collaboration revenue of $0.8 million for the quarter, a notable increase from the previous year. R&D expenses rose to $27.2 million, driven by the progression of key trials and increased manufacturing activities.
Century is also executing a strategic review of its pre-clinical pipeline to align with its high-value programs and has made organizational changes to enhance efficiency. The company plans to conclude and disclose the results of this review in early 2025.
With a continued focus on autoimmune diseases and innovative cell therapies, Century is poised to make significant strides in advancing its treatment portfolio and addressing unmet medical needs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.